In vitro drug testing using patient-derived ovarian cancer organoids

• Egile Nagusiak: Lin-Yu Chen (Egilea), Yu-Ting Chou (Egilea), Phui-Ly Liew (Egilea), Ling-Hui Chu (Egilea), Kuo-Chang Wen (Egilea), Shiou-Fu Lin (Egilea), Yu-Chun Weng (Egilea), Hui-Chen Wang (Egilea), Po-Hsuan Su (Egilea), Hung-Cheng Lai (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2024-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Ovarian cancer is the most lethal gynecological cancer. As the primary treatment, chemotherapy has a response rate of only 60-70% in advanced stages, and even lower as a second-line treatment. Despite guideline recommendations, which drugs will be most effective remains unclear....